Amedisys (AMED) Tops Q1 EPS by 21c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amedisys (AMED) PT Raised to $127 at Craig-Hallum
May 1, 2019 3:28 PM EDTCraig-Hallum analyst Kevin Ellich raised the price target on Amedisys (NASDAQ: AMED) to $127.00 while maintaining a Hold rating following results.
Strong start to the yearmargin expansion to slow before picking back up due to CCH acquisition... More